believe study of bimagrumab + semaglutide ada2025 #semaglutide #bimagrumab #lilly Obesity trials are evolving 👇

Clinical trial data from the STEP program (Semaglutide Treatment Effect in People with obesity) documented average weight loss of 47% of baseline body weight by week 16

Inconsistent use due to cost barriers often leads to yo-yo dosing, which worsens side effects when restarting

This includes motions, discovery, and hearings

300K+ members served Wide, affordable medication toolkit semaglutide Ozempic $1100/mo semaglutide Wegovy from $650/mo+ tirzepatide Zepbound from $650/mo+ tirzepatide Mounjaro ~$1100/mo liraglutide Saxenda Pricing varies liraglutide Victoza Pricing varies Found is not affiliated or endorsed by Novo Nordisk A/S., the owner of the registered trademarks Wegovy, Ozempic, Saxenda, Rybelsus, and Victoza, nor is it affiliated or ensorsed by Eli Lilly & Co., the owner of the registered trademarks Trulicity, Zepbound, and Mounjaro